Encouraging best practice and improve the rational use of medicines - Presentation Transcript
Pharmacist Lama Al.Homoud Director of Clinical Pharmacy Directorate / MOH MeTA Committee 1: Encouraging best practice & Improve Rational Use of Medicines
Committee Members
Dr Taher Abu-ElSamen, HHC, SG
Dr Laila Jarrar, JFDA, Drug Director
Dr Wafa Nsour, RMS , Pharmacy & Drug Director
Dr Khawla Abu Hamour, JUH , Pharmacy Director
Dr Sana Naffa, WHO
Dr Lama Al. Homoud, MOH, Clinical Pharmacy Director
Background
Clinical guidelines and treatment protocols are two of the major ways to ensure that the health care treatment options provided to populations are the best and most appropriate that the country could afford
Background
Standardization of protocols in a selected disease area by using the Rational Drug List
Increasing the acceptability/impact of RDL and reducing variation/inequity in current practices
Encouraging Best Practice / Improve Rational Use of Medicine
Evidence Based Decision Making for the (RDL)
Capacity Building in Civil Society
Priority Areas in Jordan’s MeTA Workplan
Scope of Work
Improve rational use of medicines:
Consolidation and implementation of Standard Treatment Guidelines
Working with physicians and pharmacists to improve prescribing behavior through training &continuing professional educational programs
Promoting the use of standard treatment guidelines
Improve rational use of medicines
Strategies adopted by MeTA / Jordan:
Strategy I : Assessment and gap analysis
Strategy II : Development and Implementation plan for the Standard Treatment Guidelines
Strategy III : Evaluation of a pilot area and Multi-Sectoral Dissemination
Strategy I: Assessment and gap analysis
Activities :
Assessing the current guidelines used in different sectors
Performing gap analysis of the current situation; what standards are used, what services are covered, are these standards implemented?
Strategy I: Assessment and gap analysis
Activities:
Reviewing the perception and use of the existing treatment guidelines Knowledge, Attitude and Practice Study (KAP study)
Defining the committee targets and future steps in developing , adopting or consolidating the standards
Identifying the scope, purpose and use of these guidelines
Strategy II: Development and Implementation plan for the STG
Activities :
Finalizing and approving STG
Disseminating the guidelines in the pilot area through orientation and training sessions
Involving the Hospital Pharmacy and Therapeutic committees to activate their role in the implementation and monitoring processes
Strategy III: Evaluation of a pilot area & Multi-Sectoral dissemination
Activities :
Evaluate the compliance with STG in the pilot area
Prepare an advocacy tool using evidence and figures on cost containment and efficiencies in medicine expenditure
Use Multi-Sectoral approach towards a national program to promote rational use of medicines
Work plan Sub-activities
1- Gap Analysis and situation analysis for the availability and use of STG in health facilities in Jordan:
a. Formulate a technical work group from public health institutions (MOH, JFDA, RMS and JUH)
b. Design a tool for collecting data regarding availability of the STG and the compliance to these standards
c. Conducting a comparative study with international STG
d. Analysis of findings, conclusion and recommendations
Work plan Sub-activities
2- Three regional workshops to build consensus and get feedback from all parties on the final STG draft
3- Finalizing and approving STG
4- produce copies of the STG with job aids, posters and other materials to be used in public health facilities
Performance Progress and Evaluation
.
Gap analysis and availability of existing guidelines
Strategy developed and disseminated
Finalization and approval of the STG
Dissemination of guidelines in the pilot area
Evaluate the compliance with standards in the pilot area
Continuing professional education programs
Means of Verification Performance Indicators
Gap analysis and assessment report finalized
Workshop conducted
Pilot conducted
Report to be delivered
CPE Programs done
Expected outcomes
The establishment of a multi-stakeholder approach that will be working towards increasing transparency focusing on the regulations, selection, procurement, and distribution of medicines
Strengthening governance
Maximizing cost benefit utilization of medicines by healthcare professionals
National Institute for Clinical Excellence (NICE)
An organization that is responsible for providing national guidance on promoting good health
A training workshop was conducted by NICE on Using Health Technology Assessment to inform decision-making in healthcare March 2009
Another workshop is planned for mid June 2009 to start with a pilot disease oriented STG (Hypertension)
National Institute for Clinical Excellence (NICE)
NICE involvement can be of benefit in two areas of strategic importance for improving the transparency of the way our healthcare system functions:
A) Best practice (STG), including harmonization of existing ones and methods and processes of adapting or developing new ones in high burden of disease areas
B) RDL including the methods and processes of making and listing and delisting decisions, considerations of cost effectiveness and of affordability
This presentation looks at the priorities for the w more
This presentation looks at the priorities for the work of the Medicines Transparency Alliance (MeTA) Jordan Council. It was made by Dr Lama Al Homoud at the launch of MeTA Jordan in May 2009 less
0 comments
Post a comment